From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
Aptamers
Riboswitches
mRNA vaccines
miRNAs
siRNAs
Journal
Molecular aspects of medicine
ISSN: 1872-9452
Titre abrégé: Mol Aspects Med
Pays: England
ID NLM: 7603128
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
03
02
2021
revised:
27
05
2021
accepted:
16
07
2021
pubmed:
2
8
2021
medline:
30
12
2021
entrez:
1
8
2021
Statut:
ppublish
Résumé
The functional and structural versatility of Ribonucleic acids (RNAs) makes them ideal candidates for overcoming the limitations imposed by small molecule-based drugs. Hence, RNA-based biopharmaceuticals such as messenger RNA (mRNA) vaccines, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA mimics, anti-miRNA oligonucleotides (AMOs), aptamers, riboswitches, and CRISPR-Cas9 are emerging as vital tools for the treatment and prophylaxis of many infectious diseases. Some of the major challenges to overcome in the area of RNA-based therapeutics have been the instability of single-stranded RNAs, delivery to the diseased cell, and immunogenicity. However, recent advancements in the delivery systems of in vitro transcribed mRNA and chemical modifications for protection against nucleases and reducing the toxicity of RNA have facilitated the entry of several exogenous RNAs into clinical trials. In this review, we provide an overview of RNA-based vaccines and therapeutics, their production, delivery, current advancements, and future translational potential in treating infectious diseases.
Identifiants
pubmed: 34332771
pii: S0098-2997(21)00063-7
doi: 10.1016/j.mam.2021.101003
pii:
doi:
Substances chimiques
Oligonucleotides
0
Oligonucleotides, Antisense
0
RNA, Small Interfering
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101003Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.